This author has not written his bio yet.
But we are proud to say that Dana Fowlkes contributed 51 entries already.
Tuesday, October 6 and Wednesday, October 7, Evrys Bio will be represented at the premier mid-Atlantic biotech and pharmaceutical partnering conference. Dr. Lillian Chiang, CEO and Dana Fowlkes, CBO will be representing Evrys Bio. This virtual conference has been extended to a total of four days to permit more opportunities for one on one partnering […]
Pennsylvania Biotechnology Center of Bucks County is once again in the spotlight, this time as the recipient of more than $1 million in state grants to help with research in pursuing a treatment and vaccine for COVID-19. Of 23 state awards, the biotechnology center, located next to the Doylestown Airport in Buckingham, received four grants, bringing in $1.1 million […]
Governor Tom Wolf announced that 23 awardees will receive $10 million in grant funding through the COVID-19 Vaccines, Treatments and Therapies (CV-VTT) program to support the rapid advancement of vaccines, treatments and therapies by qualified biotechnology entities in response to the COVID-19 pandemic. Evrys Bio was awarded over $300,000 to develop treatments for virus caused […]
July 22, 2020: In response to emergency research funding for COVID-19, the supplement extends testing of Evrys broad-spectrum antivirals to coronaviruses including SRAS-CoV-2. ABSTRACT
November 21, 2019 – Evrys Bio President & CEO, Lillian Chiang gives oral presentation, “Host Sirtuin-2 Protein (SIRT2) – A Validated Target for Broadly-Effective Antiviral Small-Molecule Drugs,” at the 2019 Chemical and Biological Defense Science & Technology (CBD S&T) Conference Cincinnati, OH. See the PowerPoint Presentation
Evrys Bio awarded Phase II SBIR grant from the NIH National Institute for Allergy and Infectious Disease titled, “A Single Antiviral to Treat Multiple Opportunistic Infections” (5R44AI11407902). Details are HERE
FORGE Life Science is now Evrys Bio. Read more
FORGE Life Science secures $1.0 M in bridge financing from its strategic investors.
FORGE Life Science Head of Biology, Eain Murphy, presents, “Targeting Host-cell Metabolism to Address Respiratory Viruses”, at the 6th International Society for Influenza and Other Respiratory Virus Diseases (ISIRV) Antiviral Group Conference – Advanced Respiratory Virus Therapeutics, Rockville, MD.
FORGE Life Science is awarded its first Department of Defense STTR contract (W911QY18P0300) from the Joint Project Manager Medical Countermeasure Systems. Proposal titled, “Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum Medical Countermeasure Against Marburg Virus”.
3805 Old Easton Road
Doylestown, PA 18902
View the FCOI POL_0006 FCOI_1_0
pertaining to federally funded projects
